Acoramidis Linked to Lower Mortality Through 54 Months - Takeaway - MDSpire
From the Journals
Conference News

Acoramidis Linked to Lower Mortality Through 54 Months

Early treatment was associated with sustained reductions in mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy

Share

  • 1

    Early acoramidis treatment improves survival in transthyretin amyloid cardiomyopathy.

  • 2

    Continuous therapy reduced all-cause mortality by 45%.

  • 3

    49% lower cardiovascular mortality was noted.

  • 4

    Functional capacity improved with continuous therapy.

  • 5

    Safety profiles showed no new long-term concerns.

  • 6

    Delayed initiation led to less favorable outcomes.

  • 7

    Study highlighted the need for timely treatment to enhance patient health.

  • 8

    Research funded by BridgeBio Pharma.

Original Source(s)

Acoramidis Linked to Lower Mortality Through 54 Months

  • by Andrea Surnit

  • April 3, 2026

Related Content

Low-Dose Apixaban Cuts Superficial Thrombosis Risk

Extended anticoagulation lowered symptomatic superficial vein thrombosis in patients with provoked venous thromboembolism.

AGA May Signal Lipids, Female Obesity

Sex-stratified cohort links alopecia to hyperlipidemia in both sexes and obesity in females

Mediterranean Diet Linked to Higher Levels of Mitochondrial Microproteins

Greater adherence was associated with lower oxidative stress markers in older patients.